Covera Health, the country’s leading provider of clinical analytics solutions to reduce medical misdiagnoses and improve healthcare quality, announced the integration of ScreenPoint Medical’s artificial intelligence (AI) tools into its quality analytics platform. Covera plans to leverage these tools to improve early detection of breast cancer for both patients and providers, which has been proven to drive more effective –– and often less invasive –– treatment, improving outcomes for women nationwide.
“We’re proud to announce this new program enhancement during Breast Cancer Awareness Month, and even prouder that we’re able to make such a positive contribution to the health of women nationwide,” said Ron Vianu, Covera Health co-founder and CEO.
Covera plans to announce additional improvements to the program with other third-party tools in the near future. “Integrating robust third-party applications, AI or otherwise, within the Covera Health ecosystem is an exciting step for us. The platform we’ve built connecting providers and payers allows for these quality-improving tools to reach millions of patients, virtually overnight,” explained Vianu further.
Richard Herzog, MD, FACR, Covera’s Chief Medical Officer noted that “We’re excited to be able to deliver continued value to our physician partners across the country, which has the potential to save millions of lives through earlier detection of breast cancers.”
ScreenPoint Medical’s FDA-approved Transpara® tool is the world’s first dedicated AI decision support solution for 2D and 3D mammography. It not only helps radiologists detect cancers earlier for better treatment and improved survival rates, but also reduces the rate of false positives as well.
One in every eight women will develop breast cancer in her lifetime, according to the National Breast Cancer Foundation, and more than 42,000 women in the United States will die of breast cancer this year. It is now the most common cancer among women worldwide. When breast cancer is detected early and is in the localized stage, the five-year survival rate is 99 percent, according to the American Cancer Society. Annual mammograms remain a critical tool for early detection.